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Investigation of the in vitro activities of various antibiotics
against Brucella melitensis strains
Onur KAYA, Füsun Zeynep AKÇAM, Güler YAYLI
Aim: To assess the antimicrobial susceptibility of Brucella melitensis strains in our region. Brucellosis is a common
disease in Turkey. Moreover, difficulties are encountered in the treatment process, such as long-lasting therapy, relapses,
and side effects of drugs. Hence, novel treatment approaches and the susceptibility of current antibiotics are vital.
Materials and methods: Thirty-four Brucella spp. isolated from blood samples of patients with brucellosis were included.
Minimal inhibitory concentrations for tetracycline, rifampicin, streptomycin, ciprofloxacin, doxycycline, ceftriaxone,
and levofloxacin were detected by broth microdilution.
Results: Tetracycline had the lowest and streptomycin the highest MIC50 and MIC90 values, respectively. A total of 5
strains were intermediate-susceptible and 1 strain was resistant to rifampicin.
Conclusion: Doxycycline and tetracycline seem to be quite effective antibiotics against Brucella melitensis strains.
Although streptomycin and rifampicin have high MIC levels against Brucella melitensis strains in our region,
inconsistencies between in vitro susceptibility and in vivo activity should be considered.
Key words: Brucella, MIC, susceptibility

Çeşitli antibiyotiklerin Brucella melitensis suşlarına karşı
in vitro etkinliklerinin araştırılması
Amaç: Bruselloz, Türkiye’de sık görülen bir hastalıktır. Bunun yanında tedavisinde zorluklarla karşılaşılmaktadır
(örneğin tedavi süresinin uzun olması, relapslar, ilaç yan etkileri). Bu yüzden yeni tedavi seçenekleri ve mevcut
antibiyotiklerin duyarlılıkları önemlidir. Bu kapsamda yöremizde Brucella melitensis suşlarının antimikrobiyal
duyarlılıklarının araştırılmasını amaçladık.
Yöntem ve gereç: Brusellozlu olguların kan kültürlerinden izole edilen toplam 34 Brucella spp. izolatı çalışmaya
alınmıştır. Tetrasiklin, rifampisin, streptomisin, siprofloksasin, doksisiklin, seftriakson, levofloksasinin MİK düzeyleri
broth mikrodilüsyon yöntemiyle saptanmıştır.
Bulgular: Tetrasiklin en düşük, streptomisin ise en yüksek MİK50 ve MİK90 düzeylerine sahipti. Beş suşun rifampisine
orta duyarlı, bir suşun dirençli olduğu saptanmıştır.
Sonuç: Bu sonuçlara göre doksisiklinin ve tetrasiklinin Brucella melitensis suşlarına karşı oldukça etkili antibiyotikler
oldukları görülmektedir. Yöremizde streptomisin ve rifampisinin Brucella melitensis suşlarına karşı yüksek MİK
değerleri olsa da in vitro duyarlılıkla in vivo etkinlik arasında farkında olabileceği göz önünde bulundurulmalıdır.
Anahtar sözcükler: Brucella, MİK, duyarlılık

Introduction
Brucellosis is a zoonosis caused by gram-negative microorganisms, Brucella spp. Human
brucellosis remains the most common zoonotic disease worldwide, with more than 500,000
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new cases annually. It is hyperendemic in many
Mediterranean countries, including Turkey (1-3).
The etiologic agent is usually transmitted through
the gastrointestinal tract, excoriations in skin and
mucosa, or inhalation. As brucellosis is a multisystem
disease, clinical findings might be diverse, leading to
intricacy in diagnosis. Therefore, treatment can be
delayed and may fail.
Brucella strains are intracellular pathogens that
infect host macrophages. Hence, the antibiotics to be
used for treatment should penetrate adequately into
the cell. Furthermore, a combination of antibiotics
should also be used to prevent relapse. Tetracyclines,
quinolones,
trimethoprim/sulfamethoxazole,
rifampicin, and streptomycin are commonly used
preparations for this treatment. Unfortunately,
despite these combinations, the relapse rate is almost
30% (4). Therefore, new treatment approaches and
more data on susceptibility are needed. In our study,
we aimed to examine the in vitro susceptibility of
certain antibiotics for the treatment of brucellosis.

fuchsin and thionine), and CO2 requirements. The
strains were stored at –80 °C in brain heart infusion
broth media containing 20% glycerol until studied.
The stored isolates were dissolved on the study day
and subcultures were made in duplicate. All tests
were carried out in a class II biological safety cabinet.
Antibiotics
The tested antibiotics, tetracycline (Sigma®, St.
Louis, MO, USA), doxycycline (Fako®, İstanbul,
Turkey), rifampicin (Sigma®), streptomycin (Sigma®),
levofloxacin (Aventis®, Frankfurt, Germany),
ciprofloxacin (Bayer®, İstanbul, Turkey), and
ceftriaxone (Sigma®), were prepared in accordance
with the recommendations of the Clinical and
Laboratory Standards Institute (CLSI) with relevant
solvents and diluents (5). Determination of the
minimal inhibitory concentration (MIC) was done
with 96-well plates containing Brucella broth. The
serial dilution of all of the antibiotics was done in
these wells.
Preparation of inoculum

Materials and methods
Bacteria
The isolates were collected between 1999 and
2005 from patients hospitalized at Süleyman Demirel
University’s Faculty of Medicine, Department of
Infectious Diseases and Clinical Microbiology. In
total, 34 isolates were obtained from blood cultures.
The BACTEC 9120 automated blood culture system
(Becton, Dickinson and Company; Franklin Lakes,
NJ, USA) was used for blood cultures. Brucella
species were identified according to the gramstaining properties of the bacteria, urease positivity,
oxidase testing, H2S production, dye sensitivity (basic

The prepared bacterial suspensions (adjusted to
0.5 McFarland) were added to each well to achieve
a final concentration of 5 × 105 cfu/mL (5 × 104 cfu/
well), and the plates were incubated at 35 °C in a 5%
CO2 atmosphere for 48 h. The Escherichia coli ATCC
25922 strain was used as the standard strain.
Results
All of the isolates were identified as Brucella
melitensis. The MIC50 and MIC90 values of the isolates
are given in the Table. Tetracycline had the lowest
and streptomycin the highest MIC50 and MIC90
values. For rifampicin, 5 of the strains (14.7%) were

Table. Antimicrobial susceptibility of 34 Brucella melitensis isolates.
Antibiotics
Doxycycline
Tetracycline
Rifampicin
Ciprofloxacin
Levofloxacin
Streptomycin
Ceftriaxone
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Range (μg/mL)

MIC50 (μg/mL)

MIC90 (μg/mL)

0.016-0.064
0.008-0.64
0.5-4
0.25-1
0.25-1
1-8
0.125-2

0.032
0.016
1
0.5
0.5
4
0.5

0.064
0.032
2
1
0.5
8
1
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intermediate-susceptible, and 1 (2.94%) strain was
resistant, according to the interpretive criteria for
slow-growing bacteria (Haemophilus).

1 resistant and 5 intermediate-susceptible strains can
be found. Reduced susceptibility to rifampicin may be
due to 2 factors: the low pH value of the medium and
inappropriate use of rifampicin leading to resistance.

Conclusion

Regional antimicrobial susceptibility of the
causative agent is an important factor in the treatment
of infectious diseases. Rifampicin is important in the
treatment of brucellosis, but its resistance rates may
pose a problem for our region in the future. However,
antibiotic susceptibility tests should be considered
where there is recurrent brucellosis (8). Therefore,
periodic assessment of the susceptibility of strains to
rifampicin in our region should ideally be conducted.

Brucellosis constitutes a major health problem
around the world, especially in developing countries.
Doxycycline-streptomycin
and
doxycyclinerifampicin combinations are recommended for
treatment of the disease by the World Health
Organization (6). Despite appropriate drug selection,
there are difficulties because of the long duration
of treatment, the necessity of giving some drugs
parenterally, and possible relapses. Therefore, novel
treatment approaches and susceptibility of present
antibiotics need to be adequately defined.
Tetracyclines have been generally used for the
treatment of brucellosis. In our study, MIC50 and
MIC90 values were 0.032 μg/mL and 0.064 μg/mL
for doxycycline, and 0.016 μg/mL and 0.032 μg/mL
for tetracycline, respectively. These results would be
“susceptible” according to CLSI guidelines. Other
data included from Turkey have revealed similarly
low MIC values (7-14). Therefore, the tetracycline
group of drugs for brucellosis treatment still seems
to be relevant. Although we found a lower MIC value
for tetracycline compared to doxycycline, the latter is
still preferable because it has fewer side effects and a
favorable pharmacological profile.
Rifampicin is an antibiotic with good penetration
into the cell and increased activity against Brucella
strains in an acidic pH environment (for example,
in the phagolysosomes of macrophages) (15). In 2
recent Turkey-based investigations, intermediate
susceptibility against Brucella strains was reported
at a rate of 9.5%-23% for rifampicin, and no
rifampicin resistance was detected (8,9). However,
another report by Memish et al. (16) revealed an
in vitro resistance rate of 3.5% for this antibiotic.
In our study, 5 strains (14.7%) were intermediatesusceptible and 1 strain (2.94%) was resistant, with
a similar resistance rate reported by Memish et al.
(16). There are no interpretive criteria for rifampicin
against Brucella strains in the CLSI guide. However, if
the MIC values of rifampicin are examined according
to the interpretive criteria of slow-growing bacteria,

Quinolones penetrate well into leukocytes and
macrophages, making them suitable agents for the
treatment of intracellular infections (17,18). The
MIC values for ciprofloxacin against Brucella strains
in various studies were between 0.19 and 1 μg/mL (712,14,19). In the present study, the MIC90 value for
ciprofloxacin was 1 μg/mL, and the MIC90 value of
levofloxacin was 0.50 μg/mL, parallel to the findings
of other investigations (14,19). Hence, quinolones
might be preferred in the treatment of brucellosis due
to their low MIC levels against Brucella spp. and their
good intracellular penetration.
Of the aminoglycoside antibiotics, streptomycin
and gentamicin are the preferred preparations for
the treatment of brucellosis. Despite the recognized
side effects of this group of drugs, they give
particularly good results in brucellosis with bonejoint involvement (3). In various studies, the MIC90
values for streptomycin were found to be between 0.5
and 8 μg/mL (7,10,12,14,20). In the present study, the
MIC90 value for streptomycin was 8 μg/mL; according
to CLSI guidelines, all of the strains were interpreted
as “susceptible.”
In the clinical treatment of patients with
neurobrucellosis, ceftriaxone is used in combined
treatment due to high concentrations in the
cerebrospinal fluid (2,3). Therefore, ceftriaxone
susceptibility in Brucella strains has been examined
in several studies. Data from Turkey revealed MIC90
values of 0.38-0.50 μg/mL (7,8,11). In the present
study, the MIC90 value of ceftriaxone was 1 μg/mL,
and, according to CLSI guidelines, all strains were
“susceptible” to ceftriaxone.
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In conclusion, susceptibility tests for Brucella
strains are not routinely carried out due to variable
test results, secondary to various factors such as pH
and inoculum amount (7,15). In this study, although
our data indicated certain problems with rifampicin

and streptomycin in our region, the MIC values of
both antibiotics were still high. However, it should be
considered that there may be discrepancies between
in vitro susceptibility and in vivo activities.
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